Basecamp Wealth Advisors’s CG Oncology CGON Stock Holding History

Basecamp Wealth Advisors’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18	Closed	-$747	–	2049
2025 Q4	$747	Buy	+18	New	+$745	﹤0.01%	1553

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Basecamp Wealth Advisors's CGON Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 18 shares — an estimated $747 sold.

Basecamp Wealth Advisors first reported a position in CGON in Q4 2025 and held it in 1 quarter. The position peaked at $747 in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

Basecamp Wealth Advisors reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 18 CG Oncology shares in Q1 2026, an estimated $747.
Basecamp Wealth Advisors first reported a position in CG Oncology in Q4 2025 and held it in 1 quarter.
Basecamp Wealth Advisors's CG Oncology position peaked at $747 in Q4 2025.
233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.